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摘要 
 
    肝细胞癌的发展与进程与代谢综合症紧密相关。其中，代谢综合症包括肝
脏的脂肪变性与肥胖。腺苷酸活化蛋白激酶（AMPK）是细胞内主要的能量感应
器，在营养刺激下，可以通过抑制合成代谢和促进分解代谢调节细胞的代谢平
衡。因此，AMPK 的激动剂可以被视为潜在的治疗药物治疗脂肪肝和肝癌。在这，
我们通过化学药物和高脂饲料诱导小鼠肝细胞癌，并给小鼠注射 AICAR。我们发
现，AICAR 可以抑制肝脏的脂肪合成以及白细胞介素-6（IL-6）的产生，抑制肝
脏的脂肪变性，最终减少肝脏的肿瘤发生。AICAR 还可以抑制 IL-6 的炎症信号
通路及其下游的 STAT3 的磷酸化激活。但是，短期的 AICAR 用药，对小鼠晚期
肝癌的生长没有明显的抑制作用。这些结果提示我们，代谢调控分子 AMPK 可以
作为一个很有前景的肝癌治疗靶点，长期的 AICAR 用药对于肥胖引起的肝癌防
治是有用的。 
 
 
关键词： AICAR, AMP, AMPK, 脂肪肝, 肝细胞癌
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英文摘要 
 
 
The development and progression of hepatocellular carcinoma (HCC) are closely 
associated with metabolic syndrome, including steatosis and obesity. AMP-activated 
protein kinase (AMPK), a master sensor of energy, regulates metabolic homeostasis 
by suppressing anabolism and accelerating catabolism in response to nutritional stress. 
AMPK agonists could therefore be considered as potential therapeutic drugs for 
treating hepatosteatosis and HCC. Here, by using a mouse model with high fat 
diet-induced steatosis and chemically induced HCC, we found that AICAR inhibits 
lipid synthesis and interleukin-6 (IL-6) production in the liver, and prevents steatosis, 
ultimately resulting in reduced tumorigenesis. AICAR also abrogates IL-6 signaling 
and STAT3 activation. However, short-term AICAR administration had no significant 
therapeutic benefit in advanced HCC. These results suggest that the metabolic 
regulator AMPK is a promising therapeutic target to treat HCC, and that long-term 
AICAR administration is useful for prevention of obesity-related liver cancer. 
 
 
Keywords:  AICAR, AMP, AMPK, hepatosteatosis, HCC 厦
门
大
学
博
硕
士
论
文
摘
要
库
说   明 
博士后研究工作报告的排版以全国博士后管理委员会办公室制定的统一格
式为准（参见以上排版范例），研究报告封面统一以彩色羊皮卡纸制作，颜色不
限，内页用纸为普通 A4 打印纸，单面或双面打印不限，正文字体为宋体小四。 
为更好地保护博士后研究报告的著作权，请各位博士后在博士后研究工作报
告中文摘要前加做《厦门大学博士后研究报告著作权使用声明》（具体格式见附
件 2），并在该声明中明确保密年限。 
出站时，提交 1份研究报告至厦门大学图书馆，2份给厦门大学人事处博士
后管理办公室（学校定期提交给国家图书馆）。 
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Introduction 
 
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is closely 
linked to risk factors such as preexisting alcoholic liver disease, nonalcoholic 
steatohepatitis, and infection with hepatitis B and C viruses (Naugler et al., 2007; 
Grivennikov et al., 2010). These factors are all associated with inflammation, which 
plays a critical role in tumorigenesis. In nonalcoholic steatohepatitis, a condition in 
which fat accumulates in the liver, the common underlying factor is obesity, rather 
than alcohol abuse. Obesity has been examined as a potential risk factor for HCC. 
Indeed, epidemiological studies indicate that excess body weight and obesity may 
increase cancer risk (Bianchini et al., 2002, Calle and Kaaks, 2004). In men who were 
free of cancer at enrollment, individuals with high body mass index experience a large, 
4.5-fold increase in risk of death from liver cancer during 16 years of follow-up (Calle 
et al., 2003). Obesity promotes HCC development by enhancing production of the 
cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα), which cause 
hepatic inflammation, activate the oncogenic transcription factor STAT3 and trigger 
tumorigenesis (Park et al., 2010),. Thus, there has long been a view that prevention of 
obesity and associated metabolic diseases may also decrease the risk of liver cancer.  
 
In eukaryotic cells, AMP-activated protein kinase (AMPK) is a sensor of energy and 
nutrient status, and is a master regulator of metabolic homeostasis by switching off 
anabolic pathways, including synthesis of fatty acids, triglycerides, cholesterol, and 
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proteins (Hardie, 2014; Carling et al., 2012; Hardie et al, 2012; Zhang et al, 2013). 
Therefore, AMPK is a good pharmacological target to treat metabolic diseases such as 
obesity, type 2 diabetes and cardiovascular disease (Steinberg and Kemp, 2009). At 
the same time, AMPK is also a potential cancer therapeutic (Hardie and Alessi, 2013), 
because its activation causes cell cycle arrest, presumably by suppressing most of the 
metabolic changes that occur in rapidly proliferating cells. However, whether AMPK 
should be activated or inhibited during cancer therapy remains an open question, and 
requires further investigation (Liang et al., 2013). On the one hand, AMPK activation 
during energy stress has been shown to enhance survival of cancer cells (Jeon et al., 
2012). On the other, AMPK has been found to negatively regulate aerobic glycolysis 
in cancer cells, and to suppress tumor growth in vivo (Faubert et al., 2013).  
 
AICAR (5-aminoimidazole-4-carboxamideriboside) is a membrane-permeable 
prodrug that activates AMPK (Hardie, 2014). In cells, AICAR is metabolized to the 
nucleotide ZMP, an AMP analog with similar effects on the AMPK complex (Corton 
et al., 1995), including allosteric activation, T172 phosphorylation, and protection 
from dephosphorylation. Here, we chemically triggered HCC in diet-induced obese 
mice, and treated them with AICAR. We found that long-term AICAR treatment 
prevented hepatic steatosis, decreased IL-6 production, and inhibited HCC 
development. Further, AICAR suppressed phosphorylation of the oncogenic 
transcription factor STAT3. These results suggest that AMPK is a promising target to 
treat HCC, and that long-term AICAR administration prevents obesity-related liver 
厦
门
大
学
博
硕
士
论
文
摘
要
库
cancer.  
 
Materials and Methods 
 
Animals and chemical induction of liver tumors 
To induce HCC, C57BL/6 mice received a single intraperitoneal (i.p.) injection of 
diethylnitrosamine (DEN) (25 mg/kg, Sigma) at 2 weeks of age. Starting at 6 weeks 
of age and continuing until sacrifice, mice were fed high-fat diet (HFD, 60% fat, 20% 
carbohydrate, and 20% protein based on caloric content; D12492, Research Diets, 
New Brunswick, NJ, USA) and received once every other day i.p. injections of PBS 
or AICAR (350 mg/kg, Toronto Research Chemicals Inc.). Tumors in the liver were 
counted and measured with a caliper, and liver tissues were promptly collected and 
frozen for biochemical, histological and immunochemical analyses. Mouse studies 
were conducted in the Laboratory Animal Center at Xiamen University.  
 
Histological, immunohistochemical, and immunofluorescence assay 
Large lobes were fixed in 10% formalin for 24-48 h. Paraffin-embedded liver tissues 
were stained with hematoxylin-eosin (H&E) , Mason stain and anti-IL-6 antibody 
(Abcam). Frozen tissue sections were stained with Oil Red O to visualize lipids.  
 
Determination of cytokines and ALT in serum  
 IL-6, TNF-α and alanine aminotransferase (ALT) in serum were determined using 
厦
门
大
学
博
硕
士
论
文
摘
要
库
kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).  
 
Measurement of triacylglyceride 
Serum and liver triacylglyceride (TAG) contents were measured using Labassay 
triglyceride reagent (290-63701, Wako Pure Chemical Industries, Ltd.).  
 
Western blotting 
Liver samples were homogenized in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 
1 mM β-glycerolphosphate, 1 mM sodium orthovanadate, and protease inhibitor 
cocktail). Equal amounts of liver homogenate (25 μg of total protein) were subjected 
to Western blotting. Blots were probed with antibodies against phosphorylated AMPK, 
AMPK, phosphorylated STAT3 (Cell signaling), β-actin (Sigma), STAT3 (Proteintech) 
and IL-6 (Abcam). 
 
RNA isolation and real-time PCR 
Total RNA was extracted with Trizol reagent (Invitrogen), and used as template to 
prepare cDNA using M-MLV RTase system (Takara). Gene expression was quantified 
using SYBR Green Real-Time PCR kit (Toyobo) and the StepOnePlus™ Real-Time 
PCR System from Applied Biosystems. 
 
Statistical Analysis 
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Student’s t test was used to test statistical significance between groups. Data are 
presented as mean ± SEM. 
 
Results 
 
AICAR inhibits DEN-induced liver tumorigenesis  
To examine whether AICAR could reduce HCC risk promoted by high-fat diet, we 
gave 2-week-old male mice a single intraperitoneal (I. P.) injection of DEN (25 
mg/kg), 4 weeks later fed the mice with HFD and administrated AICAR (350 mg/kg) 
to them once every other day (Figure S1, protocol 1). Nuclear magnetic resonance 
(NMR) imaging showed that AICAR-treated mice developed fewer HCC nodules at 
eight months than control, PBS-treated mice (Figure 1A). At 10 months of age, mice 
that received AICAR developed strikingly fewer HCCs per liver (Figure 1B, left 
panel). Furthermore, the number of tumors, as well as the size of the largest tumors, 
was dramatically reduced (Figure 1B). In addition, relative liver weight decreased 
significantly with AICAR administration (Figure 1B). Relative liver weight is the 
weight of the liver normalized to body weight. Lastly, AICAR mice gained less 
weight (Figure 1C). Thus, AICAR suppresses DEN-induced hepatocarcinogenesis. 
 
Short-term AICAR treatment exhibits no significant effect in advanced HCC 
To test whether AICAR has therapeutic benefit in advanced HCC, we administered 
the prodrug at 32 weeks, at which point mice had already developed HCC nodules 
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(Figure S2, protocol 2). The short-term treatment lasted for the next two months. 
Tumor size did not reduce notably after a month of treatment (Figure 2A). Finally, we 
found that AICAR administration over two months did not significantly decrease the 
number of tumors, the weight of the largest tumor, and the relative weight of the liver. 
Therefore, short-term administration of AICAR does not confer therapeutic benefits in 
late-stage HCC. 
 
AICAR prevents HFD-induced hepatosteatosis 
Using histological analysis, we investigated whether AICAR could prevent 
HFD-induced hepatosteatosis, which is known to accelerate liver tumorigenesis (Park, 
2010). H&E staining showed further marked ballooning in the liver of control mice 
(Figure 3A). Consistent with this result, Oil Red staining indicated that AICAR 
reduced the volume of lipid droplets in the liver (Figure 3B). In addition, TAG levels 
in both the liver and serum decreased with AICAR administration (Figure 3C and 3D). 
Finally, Mason staining showed decreased abundance of collagen fibers in 
AICAR-treated mice (Figure 3E), indicating that liver fibrosis has been suppressed. 
 
Furthermore, mRNA levels of citrate cleavage enzyme (ACL) and fatty acid synthase 
(FAS), which are both involved in lipid synthesis, decreased in AICAR treated mice 
(Figure 3F). However, AICAR did not affect mRNA levels of CD36, carnitine 
palmitoyltransferase (CPT1), and adipose triacylglyceride lipase (ATGL), which are 
involved in lipid uptake, oxidation, and lipolysis respectively (Figure S3). These data 
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indicate that AICAR suppressed hepatosteatosis which could be attributed to 
attenuated lipogenesis. 
  
AICAR suppresses IL-6 production and STAT3 phosphorylation  
Obesity enhances production of the inflammatory cytokines IL-6 and TNF-α, which 
are both critical to obesity-promoted HCC onset and development (Park et al., 2010). 
To test whether the effects of AICAR are related to the activity of these cytokines, we 
determined the levels of IL-6 and TNF-α in the serum. IL-6 levels significantly 
decreased in AICAR mice (Figure 4A). Consistent with this result, AICAR also 
lowered the abundance of IL-6 mRNA and protein in the liver (Figure 4B-C). On the 
other hand, levels of TNF-α also decreased, although not to a statistically significant 
extent (Figure 4A). Using ALT as marker, we also found AICAR administration to 
protect the liver from injury (Figure 4D). 
 
As has been seen, short-term AICAR treatment does not affect the progression of 
late-stage HCC (Figure 2), suggesting that AICAR inhibits liver tumorigenesis 
through a chronic, long-term process. Thus, we compared IL-6 abundance in mice at 
three months and six months (Figure 4E). At three months, control and AICAR mice 
have similar body weight (Figure 1C), hepatic lipid content (Figure S4A, left panel) 
and liver IL-6 levels (Figure 4E, left panel). However, at six months of age, 
AICAR-treated mice have lower body weight (Figure 1C), and have reduced levels of 
lipids (Figure S4A, right panel) and IL-6 in the liver (Figure 4E, right panel). These 
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results suggest that AICAR reduced lipid accumulation in liver via a chronic process 
that ultimately results in suppressed IL-6 production.  
 
Additionally, we performed Western blotting to determine the effect of AICAR on the 
phosphorylation of STAT3, which is a downstream target of IL-6 signaling in the liver. 
Mice at three or six months of age were sacrificed 1 h after injection with PBS or 
AICAR. Liver sections were collected promptly, and flash-frozen in liquid nitrogen. 
Liver homogenates were then subjected to Western blotting (Figure 4F). Notably, 
AICAR increased the phosphorylation of AMPK at T172 and diminished 
phosphorylation of STAT3 at Y705 in both the three month- and six month-old livers 
(Figure 4F). In addition, we found AICAR mitigated DEN effect on phosphorylation 
of STAT-3 in vivo (Figure S4B), by analyzing normal diet-fed mice that were killed 1 
h after injection with DEN (100 mg/kg) and AICAR. DEN administration could 
induce rapid production of IL-6 and phosphorylation of STAT-3 (Naugler et al., 2007). 
However, AICAR abrogated DEN-induced phosphorylation of STAT-3 (Figure S4B). 
Hence, AICAR represses DEN-induced cytokine production and signaling, 
presumably through its AMP-like effects on AMPK, which has previously been 
shown to suppress IL-6-dependent inflammation in the mouse liver (Nerstedt et al., 
2013; Cansby et al., 2014).  
 
Discussion 
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HFD promotes hepatic steatosis in DEN-treated mice, and thereby enhances the onset 
and progression of tumorigenesis in liver. Thus, disrupting hepatic steatosis may 
prevent liver cancer. Indeed, mice deficient in heat shock transcription factor 1 exhibit 
decreased chronic hepatic steatosis and dramatically reduced tumorigenesis after DEN 
administration (Jin et al., 2011). Metformin also protects mice from chemically 
induced liver tumors by inhibiting pathways that drive hepatic lipogenesis (Kavita et 
al., 2012). However, the protective effect of metformin is believed to be independent 
of AMPK activation (Kavita et al., 2012). Nevertheless, there is evidence that AMPK 
agonists represent a class of promising agents that could prevent hepatic steatosis. 
These compounds would activate AMPK in vivo and thus regulate lipid metabolism in 
the liver. For example, resveratrol, a natural polyphenol in red wine, and S17834, a 
synthetic polyphenol, potently and persistently stimulate AMPK kinase activity, and 
inhibit lipid accumulation in the liver (Li et al., 2011). Salicylate, a plant product, 
could also directly activate AMPK and increase fat utilization in mice (Hawley et al., 
2012). These compounds could be considered as candidate anti-cancer drugs for 
HCC.  
 
In this study, we showed for the first time that AICAR, a membrane-permeable 
AMPK agonist, prevents lipid accumulation in the liver, and suppresses chemically 
induced HCC development (Figure 1 and Figure 3). Our results are the first 
demonstration of the effects of AICAR on primary hepatocellular carcinoma in vivo, 
even though it has already been shown to inhibit cancer cell growth and tumor 
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development in vitro and in xenograft models (Swinnen et al., 2005). However, a 
short-term AICAR regimen has no obvious effects in advanced HCC (Figure 2). Thus, 
AICAR may not be suitable to treat late-stage liver cancer. 
 
Further, we demonstrated that AICAR reduced lipid accumulation in liver via a 
chronic process that ultimately results in suppressed IL-6 production (Figure 4). 
Obesity-associated chronic elevation in IL-6 is an important contributing factor to 
liver tumorigenesis (Park et al., 2010). In addition, IL-6 is a risk indicator, and is 
strongly correlated with poor prognosis in HCC (Porta et al., 2008). Further, IL-6 
expression is elevated in HCC progenitor cells, and the progression of these cells to 
HCC depends on autocrine IL-6 (He et al., 2013). These indicate that IL-6 is a tumor 
promoting cytokine and AICAR decreased IL-6 levels which may account for HCC 
suppression. 
 
An additional mechanism through which AICAR might suppress HCC is to enhance 
cancer cell death. Indeed, HCC in obese mice exhibits reduced apoptotic cell death 
relative to HCC in lean mice (Park et al., 2010), even though obese mice experience 
greater liver damage from DEN administration. Thus, AICAR might also, conceivably, 
prevent cancer development by reversing the ability of HCC cells to survive in the 
obese liver. Unexpectedly, we found that AICAR reduces apoptotic cell death (Figure 
4A) and compensatory proliferation (Figure 4B), even though it promotes apoptosis in 
many cancer cell lines in vitro. The mechanism underlying this effect is unknown, and 
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